Research Study for Previously Untreated Metastatic Pancreatic Cancer


Name of Study: Phase II Study of Gemcitabine and nab-Paclitaxel in Combination with Vismodegib (GDC-0449;Hedgehog Inhibitor) in Patients with Previously Untreated Metastatic Adenocarcinoma of the Pancreas

Eligibility

  • Patients with metastatic pancreatic cancer (cancer that has spread to other parts of the body) that has not yet been treated.
  • If previously treated with chemotherapy or radiation therapy after surgery (adjuvant therapy), must be at least 3 weeks since last dose of chemotherapy.

About the Study

This trial for pancreatic cancer uses chemotherapy together with a medication (GDC-0449) that inihbits a protein called Hedgehog. The Hedgehog protein has recently been found to foster the growth of pancreatic cancer cells. The drug GDC-0449 is given along with chemotherapy agents.

This study includes tests that attempt to better understand this therapy, including pre and post treatment biopsies. The safety of GDC-0449 when combined with gemcitabine and nab-paclitaxel (Abraxane) will also be assessed.

Participants will receive Gemcitabine, nab-Paclitaxel, GDC-0449.

  1. Gemcitabine nab-Paclitaxel on days 1, 8, and 15 of a 28 day cycle
  2. After the first cycle, subsequent cycles will be given in combination with oral GDC-0449 150 mg daily

For more information about this trial

  • For study related questions, call Maryanne Redlinger, Clinical Research Nurse Coordinator 215-662-7452.
  • To make an appointment with a Penn Medical Oncologist who can tell you about this and other trials, as well as treatment for pancreatic cancer call 1-800-789-PENN (7366).